Atopic Dermatitis Highlights From AAD Summer Meeting 2021

Jonathan Silverberg, MD, PhD, MPH


August 25, 2021

Dr Jonathan Silverberg, from George Washington University in Washington, DC, offers insight on key findings on atopic dermatitis presented at the AAD Summer Meeting 2021.

First, he discusses a study that found that the families of children with severe atopic dermatitis treated with dupilumab had significant improvements in their quality of life.

Next, Dr Silverberg analyzes a study that looked at dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis. It shows that the mechanism of dupilumab may inadvertently activate the Th1 and Th17 pathways implicated in psoriasis pathogenesis.

He then discusses an analysis that looks at cutaneous T-cell lymphoma development after biologic therapy and the takeaway physicians should consider when diagnosing severe inflammatory skin diseases, such as atopic dermatitis.

Finally, he highlights emerging agents in biologic, oral, and topical therapies examined by studies presented at the meeting.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.